Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
Deborah Ayeni, Braden Miller, Alexandra Kuhlmann, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Molecular targeted therapy for anticancer treatment
Hye‐Young Min, Ho‐Young Lee
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1670-1694
Open Access | Times Cited: 253
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment
Clelia Madeddu, Clelia Donisi, Nicole Liscia, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6489-6489
Open Access | Times Cited: 83
EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Alexandra Kuhlmann-Hogan, Thekla Cordes, Ziyan Xu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 3, pp. 524-545
Closed Access | Times Cited: 16
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 2, pp. e003026-e003026
Open Access | Times Cited: 64
Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
Shanshan Chen, Jingyi Tang, Fen Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 24
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Martin Gutierrez, Wei‐Sen Lam, Matthew D. Hellmann, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1718-1727
Closed Access | Times Cited: 23
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
Kohei Shitara, Maria Di Bartolomeo, Mario Mandalà, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006920-e006920
Open Access | Times Cited: 15
Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment
Chao Wang, Kailun Fei, Lihui Liu, et al.
Thoracic Cancer (2023) Vol. 14, Iss. 19, pp. 1843-1856
Open Access | Times Cited: 11
RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC
Wei Zhang, Jiawen Wang, Jialu Liang, et al.
British Journal of Cancer (2025)
Closed Access
EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
Carolin Selenz, Anik Compes, Marieke Nill, et al.
Cancers (2022) Vol. 14, Iss. 16, pp. 3943-3943
Open Access | Times Cited: 18
Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients
Dan Yan
Biomedicines (2023) Vol. 11, Iss. 11, pp. 2916-2916
Open Access | Times Cited: 7
Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings
Mounika Goruganthu, Anil Shanker, Mikhail M. Dikov, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 20
Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development
Anna Arnal Estape, Giorgia Foggetti, Jacqueline H. Starrett, et al.
Cold Spring Harbor Perspectives in Medicine (2021) Vol. 11, Iss. 12, pp. a037820-a037820
Open Access | Times Cited: 16
Construction of a nomogram model based on biomarkers for liver metastasis in non‐small cell lung cancer
Tian Zhang, Yajuan Zhang, Yunfeng Ni, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 26, pp. 1897-1911
Open Access | Times Cited: 1
Targeting the ERβ/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy
Abdulaziz A. Almotlak, Mariya Farooqui, Adam C. Soloff, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 81-81
Open Access | Times Cited: 9
Concordance between single-nucleotide polymorphism–based genomic instability assays and a next-generation sequencing–based homologous recombination deficiency test
Răzvan Cristescu, Xiao Qiao Liu, Gladys Arreaza, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 6
EGFR-Tyrosine Kinase Inhibitors Induced Activation of the Autocrine CXCL10/CXCR3 Pathway through Crosstalk between the Tumor and the Microenvironment in EGFR-Mutant Lung Cancer
Sook Hee Hong, Nahyeon Kang, Okran Kim, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 124-124
Open Access | Times Cited: 5
Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse
Aria Vaishnavi, Conan G. Kinsey, Martin McMahon
Cold Spring Harbor Perspectives in Medicine (2023) Vol. 14, Iss. 1, pp. a041385-a041385
Closed Access | Times Cited: 2
Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer
Fedor V. Moiseyenko, Ekatherina Sh. Kuligina, А. С. Жабина, et al.
International Journal of Clinical Oncology (2022) Vol. 27, Iss. 5, pp. 850-862
Open Access | Times Cited: 4
The Binary Classification of Protein Kinases
Zeev Elkoshi
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 929-947
Open Access | Times Cited: 4
Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions
Melissa Wang, Kaitlin Sparrow, Chrystal Chan, et al.
Respiratory Medicine (2022) Vol. 206, pp. 107093-107093
Closed Access | Times Cited: 3
Nuclear EGFR in breast cancer suppresses NK cell recruitment and cytotoxicity
Angelica Escoto, Ryan Hecksel, Chance Parkinson, et al.
Oncogene (2024)
Open Access
Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma
Camila Robles-Oteíza, Deborah Ayeni, Stellar Levy, et al.
Disease Models & Mechanisms (2021) Vol. 14, Iss. 11
Open Access | Times Cited: 1
EGFR+lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth
Alexandra Kuhlmann-Hogan, Thekla Cordes, Ziyan Xu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
Lisa J. Brunet, David Alexandre, Ji‐Young Lee, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1 - Next Page

Scroll to top